Cartesian Therapeutics, Inc. (RNAC) vs Sutro Biopharma, Inc. (STRO)

Cartesian Therapeutics, Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. Cartesian Therapeutics, Inc. and Sutro Biopharma, Inc. are of similar size ($199.1M and $190.0M). Sutro Biopharma, Inc. grew revenue faster over the last twelve months: −56.3% against −94.8%. Cartesian Therapeutics, Inc. has the higher net margin (0.00% vs −395.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Cartesian Therapeutics, Inc. leads on 9 and Sutro Biopharma, Inc. on 6.

Valuation

Metric RNAC STRO Biotechnology median
P/E n/m n/m 8.50
P/S 104.09 3.94 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 56.47 0.52 9.21
Earnings yield (94.58%) (159.37%) (33.15%)
Free cash flow yield (42.55%) (80.84%) (25.50%)

Profitability

Metric RNAC STRO Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (319.57%) 0.00%
Net margin 0.00% (395.25%) 0.00%
Free cash flow margin 0.00% (318.63%) 0.00%
Return on equity 236.88% 266.76% (56.36%)
Return on assets (42.77%) (79.08%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RNAC STRO Biotechnology median
Revenue growth (TTM) (94.81%) (56.25%) 6.02%
EPS growth (last fiscal year) (11.80%) 24.02% 30.26%
Revenue growth, 5-year CAGR (29.96%) 19.12% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RNAC STRO Biotechnology median
Debt to equity (0.42) 0.00 0.00
Current ratio 7.48 3.32 4.72
Net debt to EBITDA 0.89 0.92 0.96

Dividend

Metric RNAC STRO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric RNAC STRO Biotechnology median
Market cap 199.08m 190.02m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack